Drug-herb interactions represent a significant and often underestimated source of adverse drug events, arising from the concurrent use of conventional medications and herbal or botanical supplements. The use of herbal products is widespread, with estimates suggesting that 20 to 40 percent of patients in developed countries regularly use complementary and alternative medicine, often without disclosing this use to their healthcare providers. Herbal products contain multiple pharmacologically active compounds that can interact with prescription and over-the-counter medications through the same pharmacokinetic and pharmacodynamic mechanisms as conventional drug-drug interactions.
St. John’s Wort (Hypericum perforatum) is the herbal product with the greatest number of documented clinically significant drug interactions. It is a potent inducer of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein, and its effects persist for up to two weeks after discontinuation due to the time required for enzyme synthesis. By inducing these metabolic and transport pathways, St. John’s Wort reduces the plasma concentrations and efficacy of numerous medications, including cyclosporine, tacrolimus, oral contraceptives, warfarin, simvastatin, digoxin, and many antiretroviral and anticancer drugs. The interaction with cyclosporine has caused transplant rejection, and the interaction with oral contraceptives has resulted in unintended pregnancies. Patients should be specifically questioned about St. John’s Wort use, and concurrent use with drugs that have narrow therapeutic indices should be avoided.
Ginkgo biloba is widely used for cognitive enhancement and peripheral vascular disease. It inhibits platelet-activating factor and has antiplatelet properties, creating a pharmacodynamic interaction with anticoagulant and antiplatelet medications. Concurrent use of ginkgo with warfarin, aspirin, or clopidogrel increases bleeding risk, and spontaneous bleeding events, including intracranial hemorrhage, have been reported. Ginkgo also interacts with certain anticonvulsants: it can reduce the efficacy of valproic acid and increase the risk of seizures, possibly through proconvulsant constituents. Additionally, ginkgo inhibits CYP2C19, potentially increasing concentrations of drugs metabolized by this enzyme, such as proton pump inhibitors and certain antidepressants.
Ginseng (Panax ginseng) has complex and variable effects on drug metabolism and pharmacodynamics. It inhibits CYP2C9 and CYP3A4 in vitro, but clinical studies show inconsistent effects on drug concentrations. The most clinically significant interaction is with warfarin, where ginseng has been reported to reduce the anticoagulant effect, potentially through induction of warfarin metabolism or through procoagulant effects. Ginseng also interacts with MAOIs, potentially producing manic symptoms, and with antidiabetic medications through its hypoglycemic effects, which can increase the risk of hypoglycemia. The quality and composition of ginseng products vary widely, further complicating prediction of interactions.
Echinacea, commonly used for prevention and treatment of the common cold, interacts with immunosuppressant medications through pharmacodynamic antagonism. Echinacea stimulates immune function through activation of macrophages, natural killer cells, and cytokine production, which may theoretically reduce the efficacy of immunosuppressants such as cyclosporine, tacrolimus, and corticosteroids. While clinical evidence for this interaction is limited, concurrent use is generally discouraged in transplant recipients and patients with autoimmune diseases. Echinacea also inhibits CYP3A4 and CYP1A2, potentially increasing concentrations of drugs metabolized by these enzymes, though the clinical significance of these effects appears modest.
Kava (Piper methysticum) has been associated with hepatotoxicity, and this risk is increased when combined with other hepatotoxic medications. Kava inhibits CYP450 enzymes, including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, potentially increasing the concentrations of drugs metabolized by these pathways. The additive sedative effects of kava with benzodiazepines, alcohol, and other CNS depressants can produce excessive sedation and respiratory depression. Kava has been banned or restricted in many countries due to hepatotoxicity concerns.
Prevalence of herbal use varies by population and geographic region but is consistently high among patients with chronic diseases, including those taking multiple medications. Factors associated with herbal use include older age, higher education, female sex, and the presence of conditions such as cancer, arthritis, and chronic pain.
Clinical assessment of potential drug-herb interactions requires routine, non-judgmental questioning about all complementary and alternative medicine use, including specific product names, doses, and frequency of use. Reliable information about interactions can be obtained from resources such as the Natural Medicines Comprehensive Database, the US National Center for Complementary and Integrative Health, and specialized clinical pharmacology databases. When interactions are identified, strategies include discontinuing the herbal product, selecting an alternative herb or medication without interaction potential, adjusting medication doses, and monitoring clinical response and drug concentrations more closely.
